No Data
No Data
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $13
Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In...
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
Aclaris Therapeutics Highlights Drug Progress and Financial Strength
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy